Getein Biotech (603387.SS) Stock Price
Getein Biotech Price
Revenue has compounded at 22.7% per year over the past 13 years to 1.05 B CNY. Earnings per share have grown at 19.4% per year over the last 13 years. Getein Biotech's net margin stands at 21.0%, down from 28.5% several years earlier. Getein Biotech currently offers a dividend yield of about 1.91%. The payout ratio is around 38% of earnings. The dividend has grown at 6.3% per year over the past 7 years. The stock trades about 25% above its 52-week low.
Getein Biotech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Getein Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Getein Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Getein Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Getein Biotech Price |
|---|---|
| 9/18/2026 | 9.42 CNY |
| 9/17/2026 | 9.48 CNY |
| 9/16/2026 | 9.21 CNY |
| 9/15/2026 | 9.08 CNY |
| 9/14/2026 | 9.19 CNY |
| 9/11/2026 | 9.09 CNY |
| 9/10/2026 | 9.23 CNY |
| 9/9/2026 | 9.47 CNY |
| 9/8/2026 | 9.45 CNY |
| 9/7/2026 | 9.22 CNY |
| 9/4/2026 | 9.27 CNY |
| 9/3/2026 | 9.30 CNY |
| 9/2/2026 | 9.37 CNY |
| 9/1/2026 | 9.52 CNY |
| 8/31/2026 | 9.32 CNY |
| 8/28/2026 | 9.33 CNY |
| 8/27/2026 | 9.41 CNY |
| 8/26/2026 | 9.53 CNY |
| 8/25/2026 | 9.34 CNY |
| 8/24/2026 | 9.13 CNY |
| 8/21/2026 | 9.42 CNY |
| 8/20/2026 | 9.65 CNY |
| 8/19/2026 | 9.27 CNY |
| 8/18/2026 | 9.42 CNY |
| 8/17/2026 | 9.39 CNY |
| 8/14/2026 | 9.32 CNY |
| 8/13/2026 | 9.43 CNY |
| 8/12/2026 | 9.25 CNY |
| 8/11/2026 | 9.20 CNY |
| 8/10/2026 | 9.32 CNY |
Getein Biotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Getein Biotech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB CNY |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB CNY |
| EBITM CNY |
| EBIT MARGIN% |
| NET INCOMEM CNY |
| NET INCOME GROWTH% |
| DIVIDENDDIV.CNY |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.07 | 0.15 | 0.21 | 0.28 | 0.37 | 0.49 | 0.69 | 0.97 | 1.12 | 1.40 | 1.82 | 1.37 | 1.16 | 1.05 |
| – | 110.96 | 36.36 | 31.43 | 33.70 | 32.25 | 40.57 | 41.11 | 16.01 | 24.76 | 29.98 | -24.82 | -14.97 | -9.71 |
| 86.30 | 83.12 | 83.81 | 82.61 | 81.03 | 81.76 | 79.01 | 72.62 | 63.05 | 65.38 | 63.15 | 64.94 | 67.87 | 69.74 |
| 0.06 | 0.13 | 0.18 | 0.23 | 0.30 | 0.40 | 0.54 | 0.70 | 0.71 | 0.92 | 1.15 | 0.89 | 0.79 | 0.73 |
| 21.00 | 68.00 | 80.00 | 111.00 | 152.00 | 223.00 | 282.00 | 398.00 | 377.00 | 452.00 | 563.00 | 306.00 | 258.00 | 257.00 |
| 28.77 | 44.16 | 38.10 | 40.22 | 41.19 | 45.70 | 41.11 | 41.12 | 33.57 | 32.26 | 30.92 | 22.35 | 22.16 | 24.45 |
| 21.00 | 65.00 | 75.00 | 105.00 | 138.00 | 193.00 | 249.00 | 339.00 | 304.00 | 398.00 | 498.00 | 279.00 | 223.00 | 220.00 |
| – | 209.52 | 15.38 | 40.00 | 31.43 | 39.86 | 29.02 | 36.14 | -10.32 | 30.92 | 25.13 | -43.98 | -20.07 | -1.35 |
| – | – | – | – | – | – | 0.12 | 0.15 | 0.20 | 0.18 | 0.34 | 0.40 | 0.19 | 0.18 |
| – | – | – | – | – | – | – | 25.00 | 33.33 | -10.00 | 88.89 | 17.65 | -52.50 | -5.26 |
| 468.82 | 468.82 | 468.82 | 375.18 | 377.89 | 509.44 | 524.35 | 514.28 | 498.32 | 527.41 | 503.46 | 507.57 | 515.92 | 468.82 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Getein Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Getein Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Getein Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Getein Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Getein Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Getein Biotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Getein Biotech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Getein Biotech business model & stock analysis
Getein Biotech Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Getein Biotech historical P/E ratio, EBIT multiple, and P/S ratio
Getein Biotech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Getein Biotech's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Getein Biotech's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Getein Biotech's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Getein Biotech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Getein Biotech stock splits
Since 2018, a total of 3.8416000000000006 shares have been converted from one Getein Biotech share.
Getein Biotech Dividend History
9 years of dividend payments
Getein Biotech dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Getein Biotech dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Getein Biotech shareholder structure
| % | Name |
|---|---|
0.12786% | |
0.09072% | |
0.00751% |
Getein Biotech Beneficial Ownership Filings (SEC 13D/G)
Getein Biotech Executives and Management Board
10 members · avg. age 49 · 40 % women
Mr. Wen Ni (39)
Chief Financial Officer, Director · since 2017
568,000.00 CNY
Mr. Bin Yan (40)
Deputy General Manager, Director · since 2014
Ms. Tingting Kong (38)
Deputy General Manager, Director · since 2018
Mr. Enkui Su (60)
Director
Ms. Cong Liu (36)
Secretary of the Board
Mr. Enben Su (56)
Chairman of the Board, General Manager · since 2014
Mr. Suiren Wan (69)
Independent Director
Frequently asked questions about Getein Biotech
5 analysts currently rate the Getein Biotech stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Getein Biotech share trades at 1.22 EUR (9.42 CNY).
The Getein Biotech share (603387.SS) is listed on 1 stock exchanges, including: Shanghai (603387.SS).
No history available for Getein Biotech.
The revenue cannot currently be calculated for Getein Biotech.
The profit cannot currently be calculated for Getein Biotech.
The P/E ratio cannot be calculated for Getein Biotech at the moment.
The P/S cannot be calculated for Getein Biotech currently.
The Eulerpool Quality Score for Getein Biotech is 4/10.
The ISIN of Getein Biotech is CNE100002RR9. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Getein Biotech is 603387.SS. The ticker symbol is used to trade Getein Biotech shares on the stock exchange.
Over the past 12 months, Getein Biotech paid a dividend of 0.18 CNY . This corresponds to a dividend yield of about 1.91 %. For the coming 12 months, Getein Biotech is expected to pay a dividend of 0.18 CNY.
The current dividend yield of Getein Biotech is 1.91 %.
Getein Biotech pays a dividend, distributed in the months of September, June.
Getein Biotech paid dividends every year for the past 8 years.
For the upcoming 12 months, dividends amounting to 0.18 CNY are expected. This corresponds to a dividend yield of 1.91 %.
Getein Biotech is assigned to the 'Health' sector.
In the year 2025, Getein Biotech distributed 0.18 CNY as dividends.
The dividends of Getein Biotech are distributed in CNY.
Getein Biotech stock
Getein Biotech Peer Group
Getein Biotech Ticker
Getein Biotech FIGI
All fundamentals and in-depth analysis of Getein Biotech
Our stock analysis for Getein Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Getein Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.